Silence Therapeutics (NASDAQ:SLN) Coverage Initiated at Jefferies Financial Group

Equities researchers at Jefferies Financial Group initiated coverage on shares of Silence Therapeutics (NASDAQ:SLN - Get Free Report) in a research note issued on Tuesday, MarketBeat Ratings reports. The brokerage set a "buy" rating and a $40.00 price target on the stock. Jefferies Financial Group's target price points to a potential upside of 108.66% from the stock's previous close.

A number of other equities analysts have also weighed in on the stock. Chardan Capital restated a "buy" rating and set a $55.00 target price on shares of Silence Therapeutics in a research report on Friday, August 16th. Morgan Stanley raised their price objective on Silence Therapeutics from $45.00 to $49.00 and gave the company an "overweight" rating in a research report on Friday, June 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Friday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $57.20.

Silence Therapeutics Stock Up 0.4 %

NASDAQ:SLN traded up $0.08 on Tuesday, reaching $19.17. 189,476 shares of the company's stock traded hands, compared to its average volume of 212,089. The stock has a 50-day simple moving average of $18.70 and a 200-day simple moving average of $20.98. Silence Therapeutics has a 12 month low of $6.15 and a 12 month high of $27.72. The firm has a market cap of $573.76 million, a PE ratio of -16.47 and a beta of 1.29.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.10). Silence Therapeutics had a negative return on equity of 58.28% and a negative net margin of 222.44%. The business had revenue of $0.76 million during the quarter, compared to analysts' expectations of $11.28 million. On average, equities analysts anticipate that Silence Therapeutics will post -1.52 earnings per share for the current year.

Hedge Funds Weigh In On Silence Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SLN. SG Americas Securities LLC lifted its holdings in shares of Silence Therapeutics by 10.5% in the 1st quarter. SG Americas Securities LLC now owns 7,000 shares of the company's stock valued at $151,000 after acquiring an additional 667 shares during the last quarter. Quarry LP purchased a new stake in Silence Therapeutics during the second quarter valued at approximately $114,000. Marshall Wace LLP lifted its stake in shares of Silence Therapeutics by 7.3% in the 2nd quarter. Marshall Wace LLP now owns 149,397 shares of the company's stock valued at $2,839,000 after purchasing an additional 10,206 shares during the last quarter. Custom Index Systems LLC purchased a new position in shares of Silence Therapeutics in the 2nd quarter worth approximately $282,000. Finally, Lombard Odier Asset Management USA Corp boosted its holdings in shares of Silence Therapeutics by 0.7% in the 2nd quarter. Lombard Odier Asset Management USA Corp now owns 2,405,998 shares of the company's stock worth $45,714,000 after purchasing an additional 17,086 shares during the period. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.